Century Therapeutics, Inc. ((IPSC)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Century Therapeutics, Inc. is conducting the CALiPSO-1 study, officially titled A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants With Refractory B Cell-mediated Autoimmune Diseases. This Phase 1 study aims to assess the safety and efficacy of CNTY-101 in treating refractory B cell-mediated autoimmune diseases, such as systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies, and diffuse cutaneous systemic sclerosis.
The study tests CNTY-101, a biological intervention administered intravenously, alongside IL-2 and lymphodepleting chemotherapy. CNTY-101 is designed to target CD19, a protein found on the surface of B cells, to help manage autoimmune conditions.
The study is interventional, non-randomized, and follows a sequential model with no masking. Its primary purpose is treatment, focusing on confirming the appropriate dosage and expanding its application.
Key dates include the study’s start on February 5, 2024, with the latest update on June 16, 2025. These dates are crucial for tracking the study’s progress and anticipated completion.
This update could positively influence Century Therapeutics’ stock performance by showcasing their innovative approach to autoimmune diseases. Investors may view this as a promising development, especially in comparison to competitors within the biotech industry.
The CALiPSO-1 study is ongoing, with further details available on the ClinicalTrials portal.